DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukaemia, Lymphocytic, Chronic

Intervention: chlorambucil, tablets (Drug); ofatumumab (GSK1841157) infusion (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

This is an open-label study to evaluate tolerability, safety, efficacy and pharmacokinetic profile of ofatumumab in combination with chlorambucil in Japanese patients with previously untreated Chronic Lymphocytic Leukemia (CLL).

Clinical Details

Official title: A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Number of Participants Who Developed Toxicity Requiring Discontinuation From Study Treatment During Cycle 1

Number of Participants With Overall Response, as Assessed by the Independent Review Committee (IRC) With CT, IRC and Investigator

Secondary outcome:

Number of Participants With CR, as Assessed by the IRC, IRC With CT, and the Investigator

Progression-free Survival (PFS), as Assessed by the IRC and the Investigator

Overall Survival

Time to Response, as Assessed by the IRC

Duration of Response, as Assessed by the IRC

Time to Next Chronic Lymphocytic Leukemia (CLL) Therapy

Number of Participants With no B-symptoms (Constitutional Symptoms) and With at Least One B-symptom (Constitutional Symptoms) at the Indicated Time Points

Number of Participants With Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

Number of Participants With AEs of Maximum Severity

Number of Participants With the Indicated Grade 3 or Grade 4 Adverse Events

Number of Participants With the Indicated Results for Human Anti-human Antibody (HAHA) at the Indicated Time Points

Mean Change From Baseline in the Immunoglobulins (Ig) Antibodies IgA, IgG, and IgM at the Indicated Time Points

Number of Participants Who Were Positive or Negative for Minimal Residual Disease (MRD), as Assessed by IRC With CT

Change From Baseline in CD5+CD19+ and CD5-CD19+ Cell Counts at the Indicated Time Points

Beta-2 Microglobulin at Cycle 1-Day 1

Complement (CH50) at Cycle 1-Day 1 and Cycle 4-Day 85

Maximum (Peak) Plasma Concentration (Cmax) of Ofatumumab

Cmax of Serum Chlorambucil

Cmax of Serum Phenyl Acetic Acid Mustard

Minimum Plasma Concentration (Cmin) of Ofatumumab

Cmin of Chlorambucil

Cmin of Phenyl Acetic Acid Mustard

Total Plasma Clearance (CL) of Ofatumumab

Area Under the Drug Plasma Concentration-time Curve From Dosing to Time Tau (AUC[0-tau]) of Ofatumumab

AUC(0-tau) of Chlorambucil

AUC(0-tau) of Phenyl Acetic Acid Mustard

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-infinity]) for Ofatumumab

AUC(0-infinity) for Chlorambucil

AUC(0-infinity) for Phenyl Acetic Acid Mustard

Volume of Distribution at Steady State (Vss) of Ofatumumab

Plasma Half-life (t1/2) of Ofatumumab

Plasma Half-life (t1/2) of Chlorambucil

Plasma Half-life (t1/2) of Phenyl Acetic Acid Mustard

Time to Maximum Concentration (Tmax) of Ofatumumab

Time to Maximum Concentration (Tmax) of Chlorambucil

Time to Maximum Concentration (Tmax) of Phenyl Acetic Acid Mustard

Mean Residence Time to Infinity (MRTinf) of Ofatumumab

Mean Residence Time Inf (MRTinf) of Chlorambucil

Mean Residence Time Inf (MRTinf) of Phenyl Acetic Acid Mustard

Volume of Distribution (Vz) of Ofatumumab

Apparent Total Clearance of the Drug From Plasma (CL/F) for Chlorambucil

Apparent Volume of Distribution During Terminal Phase (Vz/F) of Chlorambucil

%AUC_extrap of Ofatumumab

%AUC_extrap of Chlorambucil

%AUC_extrap of Phenyl Acetic Acid Mustard

AUC (0-t) of Ofatumumab

AUC (0-t) of Chlorambucil

AUC (0-t) of Phenyl Acetic Acid Mustard

Dose Normalized Cmax (Cmax/D) for Chlorambucil

Cmax/D for Phenyl Acetic Acid Mustard

AUC (0-6)/D, AUC(0-24)/D, AUC (0-inf)/D, and AUC (0-tau)/D of Chlorambucil

AUC (0-6)/D, AUC(0-24)/D, AUC (0-inf)/D and AUC (0-tau)/D of Phenyl Acetic Acid Mustard

Detailed description: This is an open-label study to evaluate tolerability, safety, efficacy and pharmacokinetic profile of ofatumumab in combination with chlorambucil in Japanese patients with previously untreated Chronic Lymphocytic Leukemia (CLL). Ofatumumab will be infused intravenously at Day 1 (300 mg) and Day 8 (1000 mg) in the first 28-day cycle, followed by infusions of 1000 mg at the first day of each 28-day cycle. Chlorambucil will be given 10 mg/m2 at Day 1-7 in each 28-day cycle. The primary objectives are to evaluate tolerability and overall response rate (ORR) of ofatumumab with chlorambucil for previously untreated (frontline) CLL. Secondary objectives include to evaluate complete remission (CR) rate, progression free survival (PFS), overall survival (OS), time to response, duration of response, time to next therapy, incidence and severity of adverse events and serious adverse events, incidences of grade 3 and 4 infections and myelosuppression (anemia, neutropenia, thrombocytopenia), and pharmacokinetics of ofatumumab and chlorambucil.

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of CLL defined by : Circulating B lymphocytes ≥5,000 /μL AND Flow cytometry

confirmation of immunophenotype with CD5, CD19, CD20, and CD23 prior to Visit 2.

- Considered inappropriate for fludarabine-based therapy

- Active disease and indication for treatment based on modified NCI-WG guidelines

defined by presenting at least any one of the following conditions : Evidence of progressive marrow failure as manifested by development or worsening of anemia and/or thrombocytopenia. Massive (i. e. at least 6 cm below the left costal margin) or progressive or symptomatic splenomegaly. Massive nodes (i. e. at least 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy. Progressive lymphocytosis with an increase of more than 50% over a two month period or an lymphocyte doubling time of less than 6 months. A minimum of any one of the following disease-related symptoms must be present : a) Unintentional Weight loss ≥ 10% within the previous six months ; b) Fevers >38. 0 degree C for ≥ 2 weeks without evidence of infection ; or c) Night sweats for more than 1 month without evidence of infection.

- Not been previously treated for CLL (prior autoimmune hemolytic anemia treatment

permitted).

- ECOG Performance Status of 0-2.

- Life expectancy of at least 6 months, in the opinion of the investigator.

- Age ≥ 20 years.

- Signed written informed consent prior to performing any study-specific procedures.

- Patients possible to stay at the trial site for at least two days (the day of the

first infusion and a subsequent day). Exclusion Criteria:

- Prior immuno- or chemotherapy for CLL or small lymphocytic lymphoma (SLL) with any

agent except corticosteroids used to treat autoimmune hemolytic anemia.

- Previous autologous or allogeneic stem cell transplantation.

- Active autoimmune hemolytic anemia (AIHA) requiring corticosteroid therapy > 100

mg/day equivalent to hydrocortisone, or chemotherapy.

- Known transformation of CLL (e. g. Richter).

- Known CNS involvement of CLL.

- Chronic or current active infectious disease requiring systemic antibiotics,

antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C.

- Other past or current malignancy. Subjects who have been free of malignancy for at

least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.

- Clinically significant cardiac disease including unstable angina, acute myocardial

infarction within 6 months prior to screening (Visit 1), congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities.

- History of significant cerebrovascular disease or event with significant symptoms or

sequelae*.

- Glucocorticoid use, unless given in doses ≤ 100 mg/day hydrocortisone (or equivalent

dose of other glucocorticoid) for <7 days for exacerbations other than CLL (e. g. asthma).

- Known HIV positive.

- Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In

addition, if negative for HBsAg but HBcAb and/or HBsAb positive, an HBV DNA test will be performed and if positive the subject will be excluded.

- Screening laboratory values :

Creatinine > 2. 0 times upper normal limit (unless normal creatinine clearance). Total bilirubin > 2. 0 times upper normal limit (unless due to Gilbert's syndrome). Alanine transaminase (ALT) > 3. 0 times upper normal limit.

- Previous treatment or known or suspected hypersensitivity to ofatumumab that in the

opinion of the investigator or medical monitor is a contraindication to their participation in the present study.

- Treatment with any known non-marketed drug substance or experimental therapy within 5

terminal half lives or 4 weeks prior to Visit 1, whichever is longer, treatment with any anti-CD20 monoclonal antibody within 3 months of Visit 1, or participation in any other interventional clinical study. Note: Participation in any other interventional clinical study after disease progression during post PD-follow-up is permitted.

- Known or suspected inability to comply with study protocol.

- Lactating women, women with a positive pregnancy test at Visit 1 or women (of

childbearing potential) as well as men with partners of childbearing potential, who are not willing to use adequate contraception from study start through one year following last treatment dose. Adequate contraception is defined as oral hormonal birth control, intrauterine device, male partner sterilization (if male partner is sole partner for that subject) and the double barrier method (condom or occlusive cap plus spermicidal agent).

Locations and Contacts

GSK Investigational Site, Aichi 466-8650, Japan

GSK Investigational Site, Hokkaido 060-8543, Japan

GSK Investigational Site, Kanagawa 259-1143, Japan

GSK Investigational Site, Kyoto 602-8566, Japan

GSK Investigational Site, Tokyo 104-0045, Japan

GSK Investigational Site, Tokyo 135-8550, Japan

Additional Information

Starting date: April 2012
Last updated: July 16, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017